Changchun Institute of Biological Products: Clinical trial application for adolescent and adult diphtheria-pertussis vaccine approved.

Chinabiotech announced on November 11th that the adsorbed acellular pertussis combined vaccine developed by its wholly-owned subsidiary Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. has obtained the drug clinical trial approval notice from the National Medical Products Administration, allowing clinical trials to prevent infectious diseases caused by diphtheria, tetanus, and pertussis. So far, there is no component pertussis vaccine approved for adolescents and adults for use in China, and the market prospects are promising.